Ghana Begins Testing New Lassa Fever Vaccine
The study evaluates a vaccine candidate in 51 adults to address a disease that currently has no licensed immunization.
Updated on Oct. 22, 2026 in COVID-19
Live Poll
Should regional governments prioritize development of vaccines for diseases not currently present in their country?
Ghana has launched a clinical trial for an experimental Lassa fever vaccine, marking a new stage in efforts to prevent a disease that currently has no licensed immunization. The study is evaluating the safety and immune response of the ChAdOx1 LassaJ candidate in 51 healthy adults.
Why it matters
There is currently no licensed vaccine for Lassa fever, which was first identified in 1969. Researchers are testing this candidate to help prepare for potential outbreaks caused by regional human movement in areas where the disease is prevalent.
This clinical trial is enrolling 51 healthy adults aged 18 to 55 to assess the safety and immunogenicity of the ChAdOx1 LassaJ candidate. As this is an early-stage study, the findings regarding the vaccine's actual protective efficacy remain unknown.
The players
University of Oxford
A research institution currently conducting parallel Lassa fever vaccine trials in the United Kingdom.
CEPI
An international coalition that committed 24.9 million dollars to support the development of Lassa fever vaccine research.
Kintampo Health Research Centre
The specific research facility in Ghana's Bono East Region serving as the site for the human vaccine trial.
The details
The experimental vaccine utilizes the ChAdOx1 technology platform to trigger a human immune response against the Lassa virus. Participants at the Kintampo Health Research Centre are receiving doses of the candidate as researchers monitor for safety markers. This effort aims to establish a baseline for preventing the virus, which could theoretically save an estimated 3,300 lives over a decade.
Timeline
1969: Lassa fever was first identified in Lassa, Nigeria.
October 14, 2026: The clinical trial began in Ghana.
Health Landscape
The use of the ChAdOx1 technology platform reflects ongoing efforts to adapt viral vector approaches for emerging pathogens. This study represents a key step in the broader search for a Lassa fever vaccine to replace the current lack of available immunizations.
This research is currently in the experimental stage and does not offer immediate personal health changes. While the development is a significant step for global outbreak preparedness, clinical findings regarding safety and efficacy must still undergo rigorous review.
The takeaway
The launch of this trial is a milestone in addressing a disease that has lacked a preventive vaccine for decades. Readers should watch for future study results, which will determine if this candidate can eventually move toward wider clinical use.
Further reading
For more on vaccine development efforts, visit COVID-19.
Source note: This article includes information reported by Gbcghanaonline.
Live Poll
Should regional governments prioritize development of vaccines for diseases not currently present in their country?
